DUBLIN–(BUSINESS WIRE)–The “Asia Pacific Bioanalytical Testing Services Market 2021-2031 by Molecule Type, Application, Test Type, Workflow Process, Therapeutic Area, End User, and Country: Trend Forecast and Growth Opportunity” report has been added to ResearchAndMarkets.com’s offering.
Asia Pacific bioanalytical testing services market will grow by 11.2% annually with a total addressable market cap of $13,359.1 million over 2022-2031, driven by the rising demand for analytical testing of biologics and biosimilars amid COVID-19 pandemic, increasing preference for outsourcing analytical testing, growing R&D expenditure in the pharmaceutical and biopharmaceutical industries, and the rising adoption of the Quality by Design (QbD) approach.
In-depth qualitative analyses include identification and investigation of the following aspects:
- Market Structure
- Growth Drivers
- Restraints and Challenges
- Emerging Product Trends & Market Opportunities
- Porter’s Five Forces
Based on Molecule Type, the Asia Pacific market is segmented into the following sub-markets with annual revenue ($mn) for 2021-2031 included in each section.
- Small Molecules
- Large Molecules
- LC-MS Studies
- Immunoassays
- Other Large Molecule Tests
Based Application, the Asia Pacific market is segmented into the following sub-markets with annual revenue ($mn) for 2021-2031 included in each section.
- Bioavailability and Bioequivalence Studies
- Pharmacokinetics (PK)
- Pharmacodynamics (PD)
- Absorption, Distribution, Metabolism, Excretion (ADME)
- Other Applications
By Test Type, the Asia Pacific market is segmented into the following sub-markets with annual revenue ($mn) for 2021-2031 included in each section.
- Cell-based Assays
- Bacterial Cell-based Assays
- Viral Cell-based Assays
- Virology Testing
- In Vitro Virology Testing
- In Vivo Virology Testing
- Species-Specific Viral PCR Assays
- Serology, Immunogenicity, and Neutralizing Antibodies (SINA)
- Bacterial Serology, Immunogenicity, and Neutralizing Antibodies
- Viral Serology, Immunogenicity, and Neutralizing Antibodies
- Method Development Optimization and Validation (MDOV)
- Biomarker Testing
- Pharmacokinetic Testing
- Other Test Types
By Workflow Process, the Asia Pacific market is segmented into the following sub-markets with annual revenue ($mn) for 2021-2031 included in each section.
- Sample Preparation
- Protein Precipitation
- Liquid-liquid Extraction (LLE)
- Sample Analysis
- Hyphenated Technique
- Chromatographic Technique
- Electrophores is
- Ligand Binding Assay
- Mass Spectrometry
- Nuclear Magnetic Resonance
- Other Workflow Processes
By Therapeutic Area, the Asia Pacific market is segmented into the following sub-markets with annual revenue ($mn) for 2021-2031 included in each section.
- Oncology
- Neurology
- Infectious Diseases
- Gastroenterology
- Cardiology
- Other Therapeutic Areas
By End User, the Asia Pacific market is segmented into the following sub-markets with annual revenue ($mn) for 2021-2031 included in each section.
- Pharma and Biopharma Companies
- Contract Development and Manufacturing Organizations (CDMOs)
- Contract Research Organizations (CROs)
Selected Key Players:
- Charles River Laboratories International Inc.
- Covance Inc.
- Eurofins Scientific
- ICON PLC
- Intertek Group PLC
- IQVIA Holdings, Inc.
- Laboratory Corporation of America Holdings
- Medpace Holdings, Inc.
- Pace Analytical Services LLC.
- Parexel International Corporation
- PPD Inc.
- SGS SA
- Syneos Health, LLC
- Toxikon Corporation
- WuXi Apptech Co., Ltd.
Key Topics Covered:
1 Introduction
2 Market Overview and Dynamics
3 Segmentation of Asia Pacific Market by Molecule Type
4 Segmentation of Asia Pacific Market by Application
5 Segmentation of Asia Pacific Market by Test Type
6 Segmentation of Asia Pacific Market by Workflow Process
7 Segmentation of Asia Pacific Market by Therapeutic Area
8 Segmentation of Asia Pacific Market by End User
9 Asia-Pacific Market 2021-2031 by Country
10 Competitive Landscape
For more information about this report visit https://www.researchandmarkets.com/r/xxq5rt
The content is by Business Wire. Headlines of Today Media is not responsible for the content provided or any links related to this content. Headlines of Today Media is not responsible for the correctness, topicality or the quality of the content.
